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Abstract
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
levothyroxine improves exercise capacity in patients with thyroid disease.
SUDY DESIGN: Review of three English language primary studies published in peer-reviewed
journals in 2000, 2005, and 2009
DATA SOURCES: Two randomized control trials and one clinical trial comparing
leveothyroxine to euthryroid were found using Medline, and PubMed databases.
OUTCOMES MEASURED: Each of the three studies measured heart rate and blood pressure
before during, and after exercise in patients to determine the effect levothyroxine has on both
heart rate and blood pressure
RESULTS: One RCT found that submaximal cardiopulmonary exercise performance improved
after six months of TSH normalization. The second RCT found that with careful tailoring of
TSH-suppressive therapy there is improvement in exercise performance. The controlled clinical
trial found that restoring a patient to normal TSH levels does not produce significant changes in
substrate response to exercise.
CONCLUSIONS: The results demonstrate that the studies do not agree on the effects of
levothyroxine or euthyroid on exercise capacity.
KEYWORDS: Hypothyroidism, exercise capacity, levothyroxine
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INTRODUCTION
Hypothyroidism is a condition in which the thyroid gland doesn’t produce enough thyroid
hormone, where thyroid stimulating hormone (TSH) is greater than normal, and the thyroid
hormone (T4) levels are decreased. Thyroid hormones stimulate metabolic activities in most
bodily tissues and when levels decrease, metabolism slows.1 Major targets for thyroid hormones
are the heart and skeletal muscle. Therefore, hypothyroidism can lead to weaker heart muscle,
causing decreased cardiac output and contractility, bradycardia, and an increase in vascular
resistance.2 This can ultimately lead to a negative impact on an individual’s quality of life.
It is estimated that 10 million Americans (approximately 1% of the US population) are
diagnosed with hypothyroidism.1,3 Higher rates of hypothyroidism have been diagnosed in
women and in individuals over the age of 50.1 Although the annual cost or number of healthcare
visits is not available for the US, in Germany, data shows that iodine-deficiency hypothyroidism
costs approximately 1 billion dollars annually and inpatient care accounts for nearly $250 million
a year.4
There are several different causes of hypothyroidism. Iodine deficiency is the most
common cause of hypothyroidism worldwide. The most common form found in the US is
Autoimmune thyroiditis (Hashimoto’s disease), which can be associated with a goiter and results
in gradual loss of thyroid function. Hashimoto’s disease has a mean incidence of 4/1,000F and
1/1,000M. Congenital hypothyroidism is caused by thyroid gland dysgenesis, is present in
1/4,000 newborns and can either be transient or permanent.1
Thyroid hormone is produced in the thyroid gland using iodine. Thyroxine (T4) and
triiodothyronine (T3) are the two most important hormones. In the blood, all hormones are
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converted into T3, the active hormone that affects the metabolism of cells. Since hypothyroidism
can affect many different body systems, many individuals seek medical care due to the effects of
hypothyroidism before they are even diagnosed. Individuals will often experience: fatigue,
lethargy, anorexia, constipation, depression, menstrual changes, muscle stiffness, cold
intolerance, dry skin, memory impairment. Definitive treatment for individuals with
hypothyroidism is through the use of daily medication. Standard treatment is Levothyroxine
(Synthroid), a form of T4. The dosage of levothyroxine is based between1.0-1.7 mcg/kg/day.
Second line treatments include: Cytomel (Liothyronine), a form T3, and Armour thyroid, a
T3/T4 combination.1 Since hypothyroidism affects metabolism, it consequently affects skeletal
muscle, cardiac function, and exercise capacity (maximal physical exertion) in individuals. When
taking levothyroxine, the T4 hormone that is naturally produced in the body is replaced. This
allows the body to function with normal hormone levels, ultimately decreasing the physical,
cardiac and vascular effects of hypothyroidism within the body. In the three reviewed studies,
decreased exercise capacity is evaluated through heart rate (HR) and blood pressure (BP), along
with other factors. Being the standard treatment for hypothyroidism, levothyroxine may provide
positive outcomes in regards to exercise capacity by helping to reverse the negative effects
triggered by low thyroid hormone.
OBJECTIVE
The objective of this systematic review is to determine if levothyroxine is effective in
increasing exercise capacity in subjects with thyroid disease.
METHODS
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Studies for this systemic review were found using the key words: hypothyroidism,
exercise capacity and levothyroxine. All studies were published in peer-reviewed journals in
English. All literature searches were performed through Medline and PubMed. Inclusion criteria
for the review were: POEM, randomized controlled trials and studies that were posted in 1996 or
later. Exclusion criteria for the review included: drugs that could influence heart rate, blood
pressure or thyroid function, except levothyroxine. The statistics used in the reviewed studies
includes P-values, ANOVA, T-test, and Wilcoxon test.
Three studies (2 RCT, 1 clinical trial) were selected for this review and met the following
criterion:1) The population of participants included male and/or female subjects receiving
levothyroxine for thyroid disease; 2) Interventions used were levothyroxine either in a fixed dose
or dosed to make an individual euthyroid; 3) Comparison groups in the study were euthyroid
subjects compared to those taking levothyroxine and 4) Outcomes measured were blood pressure
and/or heart rate. A summary of the design and results of the three studies is outlined in Table 1.
The study performed by Mainenti et al. was conducted in Rio de Janeiro, Brazil at the
Federal University of Rio de Janeiro. Subjects were recruited from the outpatient Endocrine
Clinic at the University. Inclusion criteria for the study included: untreated 30-60 years old with
increased TSH >4.0 and Normal free T4 levels. Exclusion criteria used for the study were:
subjects taking drugs that alter thyroid function, HR and/or BP, an individual diagnosed with
cardiac diseases including atrial hypertension, and lastly problems that could interfere with
walking. All subjects met the inclusion and exclusion criteria of the study and gave written
consent that was approved by the ethics committee.5
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The study performed by Caraccio et al. was conducted in Pisa, Italy at the University of
Pisa School of Medicine. Individuals, aged 26-34, were recruited from the outpatient clinic with
elevated TSH levels (>3.6 mlU/liter) and Hashimoto’s thyroiditis which was verified with
positive antithyroid peroxidase and antithyroid autoantibody titers. Exclusion criterion included:
any parameters found outside of the given inclusion criteria for sex, age, BMI, body composition
and subjects without Hashimoto’s thyroiditis. Subjects had blood sampled and were evaluated
for neurologic, cardiovascular, respiratory or other systemic diseases. The study protocol was
approved by the ethics committee and all subjects signed and confirmed informed consent.6
The study performed by Mercuro et al. took place at the University of Cagliari in
Cagliari, Italy. The inclusion criteria for this study included: individuals 26-65 years old, long
term TSH-suppressive fixed dose levothyroxine therapy of 700-1575mcg for 2-20 years, a
normal free T3 and suppressed TSH < 0.1 mU/L. Exclusion criteria includes: subjects taking
drugs for cardiovascular disease or any medications other than levothyroxine. All of the subjects
were screened for cardiovascular disease or the concomitant use of other medications.7
Table 1: Demographics of included studies
Study

Design

Subjects

Age

Mainenti
et al.5;
2009

RCT

23

30-60

Caraccio
et al.6;
2005

RCT

33

26-34

Inclusion
criteria
Untreated
subjects; 3060 yo;
increased
TSH >4.0,
Normal free
T4 levels

Increased
TSH >3.6,
normal free

Exclusion
criteria
Drugs that
could change
thyroid fx,
HR, BP;
diagnosed
cardiac ds,
atrial HTN;
problems that
can interfere
with walking
Subjects that
don’t match
control group

W/D

Interventions

N/A

TSH
normalized
with
levothyroxine

N/A

12mo
levothyroxine
replacement
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Mercuro
et al.7;
2000

Clinical
Trial

38

26-65

T3&4 levels;
+
Hashimoto’s
thyroiditis, +
antithyroid
peroxidase
&
antithyroid
autoantibody
titers
Long term
therapy of
7001575mcg X
2-20 years;
normal free
T3;
suppressed
TSH < 0.1
mU/L

for sex, age,
BMI, body
composition;
Pts with
negative ds or
antithyroid
titers

to euthyroid

Cardiovascular N/A
ds; taking any
drugs other
than
levothyroxine;
No
sympatholytic
meds X 1yr

Levothyroxine
at fixed dose
of 1.8-4
mcg/kg

OUTCOMES MEASURED
The primary outcomes measured in the studies were HR and/or BP. The values were
measured before, during, and after exercise in subjects to determine the effect that levothyroxine
has on both HR and BP. In each of the three studies, subjects were monitored using an EKG
during exercise from which they could determine the HR. In the Mainenti et al. study the BP was
measured using the ausculatroy method before exercise and at three minute intervals during
exercise.5 In the Mercuro et al. study arterial BP was measured every three minutes of exercise
and at the first, fifth and tenth minute of recovery using a mercury sphygmomanometer.7
Although the studies measured HR and/or BP, the studies also looked at other
measurements. Mainenti et al. measured HR, oxygen uptake, minute ventilation and other
cardiopulmonary parameters within the fifth minute of exercise to obtain sub-maximal exercise
measurements.5 Caraccio et al. measured HR, oxygen uptake (VO2), and carbon dioxide output
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during an incremental aerobic exercise test. At rest, every two minutes during the incremental
aerobic exercise test, and during twenty minutes of recovery blood “glucose, lactate, pyruvate,
free fatty acid, glycerol and B-hydroxybutyrate concentrations” were measured.6 Mercuro et al.
evaluated cardiac function through clinical, echocardiogram and ergometabolic means. The
evaluation includes “intraventricular septum thickness, left ventricular posterior wall thickness,
end-diastolic dimension and left ventricular mass index”. “During the exercise portion of the
study exercise tolerance (maximal tolerated workload), maximal VO2, and anaerobic threshold”
was evaluated in addition to heart rate.7
RESULTS
The results from the reviewed studies were presented as continuous data, which cannot be
changed to data in the dichotomous form. Studies looked at HR and/or BP to help determine the
effects that levothyroxine has on exercise metabolism by comparing control to treated subjects.
Studies compared BP and/or HR at base line and then again at six months along with monitoring
the values during exercise. With lower HR values during exercise the heart is working more
efficiently and pumping more blood through the body with each beat. This means that at the
same level of exercise, with a lower HR one is working less hard and pumping more blood to the
tissues and organs in the body.8 The same concept is used with BP during exercise. Blood
pressure is a reflection of the resistance of blood flow through the arteries. If your BP is lower
during exercise, the heart is working less to pump blood throughout the body. A lower HR and
BP during exercise helps the body work more efficiently. With an elevated HR or BP during
exercise one may experience: decreased ability to perform exercise routines, chest pain,
palpitations, increased shortness of breath, increased fatigue, and headache.
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Mainenti et al. reported HR of untreated subjects of 129 + 17 bpm at baseline and 128 +
17 bpm at six months vs 128 +17 bpm at baseline and 121 + 17 bpm at six month follow up for
treated subjects. The p-value for HR was statistically significant with p<0.05. When compared
before and at peak exercise, both systolic and diastolic blood pressure values were not
significantly different from baseline to the six month follow-up. Systolic blood pressure (SBP) in
untreated subjects at baseline was 142.7 + 26.8 mmHg and 154.55 + 23.9 mmHg at six months.
For the treated subjects SBP was 145.5 +17.9 mmHg and 142.3 + 18.2 mmHg, respectfully. Prior
to exercise, the mean BP was “116/79 mmHg vs 120/81 mmHg (untreated) and 122/80 mmHg vs
119/80 mmHg (treated)”. At peak exercise, mean BP values were “159/90 mmHg vs 173/89
mmHg (untreated) and 158/87 mmHg vs 154/86 mmHg (treated)”.5 A summary of the results
can be found in table 2.
Table 2: Summary of BP and HR as outline in the Mainenti et al.
Study5
Untreated Subjects
Treated Subjects
(n = 12)
(n = 11)
Baseline 6 months
Baseline 6 months
HR (bpm)
SBP (mmHg)
BP mean

129 + 17
142.7 + 26.8
116/79

128 + 17
154.55 + 23.9
120/81

128 +17
145.5 +17.9
122/80

121 + 17
142.3 + 18.2
119/80

159/90

173/89

158/87

154/86

(prior to exercise)

BP mean
(at peak exertion)

The p-value was statistically significant with <0.05

Caraccio et al. reported that euthyroid subjects experienced a higher HR as the workload
increased compared to their control counterparts. This data was found to be statistically
significant with P<0.03. Resting HR in untreated subjects was 85 + 3 bpm vs 78 + 4 bpm for
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control subjects ( (table 3). Following twenty minutes of exercise, the subjects HR was about 170
bpm vs 145 bpm for the control group. Resting HR in treated subjects was 78 + 3 bpm (baseline)
vs 79 + 3 bpm (six months), whereas HR in placebo subjects was 85 + 2 bpm vs 89 + 3 bpm
respectfully.6 In follow up studies, there were no substantial differences observed between the
placebo and active treatment for HR values.
Table 3: Summary of gathered HR data
Caraccio et al. study6
Untreated
Subjects
Resting HR (bpm)
85 + 3
Exercise HR (min 10)
~145
Exercise HR (min 20)
~170
Data was significant with P<0.03

in the
Control
Subjects
78 + 4
~130
~145

Mercuro et al. reported a slightly higher HR in the experimental group compared to the
control group, with p<0.01. Resting HR was 88 + 17 bpm in subjects vs 88 + 8 bpm in the
control group. At peak exercise, HR was 96 + 6.9 bpm and 95 + 2 bpm respectfully. SBP was
133 + 25 bpm and 114 + 10 bpm respectfully and 183 + 18 bpm and 179 + 14 bpm respectfully.
In regards to BP, P<0.05.7 This data is represented in table 4.

Table 4: Mercuro et al. table of results summary7
Treated
Control

Resting HR (bpm)
Peak Exercise HR
Resting SBP (mmHg)
Peak SBP ( mmHg)
p<0.01

Subjects

Subjects

(n=9)
88 + 7
96 + 6.9
133 + 35
183 + 18

(n=9)
88 + 8
95 + 2
114 + 10
179 + 14

Hegener, Levothyroxine & exercise capacity, 11
Mainenti et al. trial looked at treated and untreated experimental groups compared the
results between baseline and six month follow up.5 The Caraccio et al. trial studied treated
subjects vs placebo both at baseline and then six month after treatment.6 Finally, the Mercuro et
al. study compared the experimental group and then the control group.7 All three studies were
without adverse affects, and therefore numbers needed to harm could not be calculated.
During all three studies, subjects were monitored at baseline and then at the six month
follow-up and all parameters were measured at several intervals during exercise. None of the
studies reported any loss of participants or adverse effects during the study causing subjects to
leave.
DISCUSSION
Hypothyroidism is a very common endocrine disorder, especially in older women.
Thyroid hormone released from the thyroid gland works to control the metabolism in the body.
When levels are low, all functions of metabolism are decreased. Levothyroixine is the treatment
of choice for hypothyroidism since it replaces T4, which is then converted into T3, the active
from of thyroid hormone.1 Since thyroid hormone is used to directly replace the hormone that is
absent in the body, it is thought that all effects of the metabolic disorder will be reversed.
The studies used participants that were being seen and some treated for sub-clinical
hypothyroidism. The participants of the studies were not on any other medication or had any
other physical ailments that would prohibit them from performing the exercise portion of the
study. All placebo or controlled subjects were matched for age, sex, BMI, and body composition.
The studies took baseline and six month follow-up measurements. In the three studies, blinding
did not seem to be compromised.

Hegener, Levothyroxine & exercise capacity, 12
The Mainenti et al. study showed that in subjects who had received levothyroxine
treatment had a decrease in HR after the six months. In the same treated group, the study found
that at peak exercise exertion, BP was lower than in the untreated group. With these results, it
was shown that at submaximal exercise, treated subjects spent less energy than the untreated
group.5
Caraccio et al. demonstrates that untreated subjects show increased HR levels when
compared to euthyroid subjects at an equal exercise intensity. The study was not able to find
significant changes in energy or response to exercise. Levothyroxine did not appear to correct the
exercise impairment found in sub-clinical hypothyroidism during the course of the study.6
Mercuro et al. was able to show that HR in subjects was slightly higher than euthyroid
individuals during exercise, but “careful adjustment of levothyroxine dose can reverse and
almost completely normalize cardiopulmonary” function.7
CONCLUSIONS
Two of the three studies show that there is a statistical difference in exercise capacity
between untreated and treated subjects and between baseline and the six month follow up. Since
there is discrepancy between the three studies, it cannot be stated that there is added benefit, for
exercise capacity, to treatment in those with subclinical hypothyroidism. Therefore, the evidence
is equivocal in determining a conclusive answer to whether or not levothyroxine is effective in
increasing exercise capacity in subjects with thyroid disease.
Even though there are many individuals diagnosed with hypothyroidism yearly, it is a
health disparity that requires further attention. Since subjects are given T4 in the form of
levothyroxine to treat their hypothyroidism, each subject could respond differently to the
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treatment, causing discrepancy in the study result. Instead of having a set TSH level in future
studies, it might be beneficial to titrate levothyroxine to symptomatic treatment and then perform
exercise studies. This would increase the chance that each individual person would be receiving
the correct amount of treatment for their body and not being based just on lab values.
If a study could be conducted on populations at high risk for the development of subclinical hypothyroidism before being diagnosed or treated, it might help determine if those who
are more active in their youth have a higher probability of responding to medicine and, thus, be
able to reverse the effects of hypothyroidism on the body.
Researchers may also consider whether Synthroid, the brand name of levothyroxine,
affects subjects significantly different compared to the generic form. If this is the case, then one
form could be prescribed more in situations where exercise capacity is decreased.
Since each of the three reviewed studies had a small subject population, it would be
beneficial to gather a larger subject population to help provide more conclusive data in the
future. Apart of the subject population for the studies should be a placebo group to help compare
results. This was not done in the Mainenti et al. study.
In conclusion, long term and larger subject trials are needed to help determine if
levothyroxine does have a positive benefit on exercise tolerance in those with hypothyroidism
since the three reviewed studies in this case review yielded inconclusive results.
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